Back Hepatitis C

Hepatitis C

AASLD Liver Meeting Starts this Weekend in Washington, DC

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this Friday, running November 1-5 at the Walter E. Washington Convention Center in Washington, DC. The highlight of this year's meeting will be numerous presentations on next-generation direct-acting antivirals (DAAs) for hepatitis C, now in late stages of development, both as interferon add-ons and in interferon-free regimens.

alt

FDA Advisory Committee Gives Positive Opinions on HCV Drugs Simeprevir and Sofosbuvir

The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) this week gave unanimous recommendations for approval of 2 next-generation direct-acting antivirals for hepatitis C, Janssen's simeprevir (formerly TMC435) and Gilead Science's sofosbuvir (formerly GS-7977 and PSI-7977).

alt

EACS 2013: New Drugs Will Bring Revolution in Hepatitis C Treatment

The advent of direct-acting antiviral agents can rightly be described as a revolution in treatment for chronic hepatitis C, but potential challenges remain including drug interactions and cost, Heinrich Wedemeyer told participants during a plenary session at the 14thEuropean AIDS Conference (EACS 2013) this week in Brussels.

alt

EACS 2013: HCV Reinfection Common Among HIV Positive Gay Men in Europe

A study found that 18% of HIV positive men acquired hepatitis C virus (HCV) a second time after clearing the virus, with some having third and fourth infections as well, according to findings from the European AIDS Treatment Network presented at the 14th European AIDS Conference this month in Brussels.

alt

IDWeek 2013: Older People Respond Equally Well to Telaprevir Triple Therapy for Hepatitis C

Interferon-based therapy with telaprevir (Incivek or Incivo) produced a similar cure rate with no notable increase in side effects or treatment discontinuation for genotype 1 chronic hepatitis C patients over age 60, Japanese researchers reported at the second IDWeek conference held recently in San Francisco.

alt

EACS 2013: Faldaprevir Demonstrates Good Early Response in Genotype 1 HIV/HCV Coinfection

The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained response at 4 weeks after completing treatment, according to a report at the 4th European AIDS Conference last week in Brussels.

alt

Janssen Acquires GSK NS5A Inhibitor Candidate for Hepatitis C

Janssen Pharmaceuticalsannounced this week that it has purchased a Phase 2 hepatitis C virus (HCV) NS5A inhibitor candidate, GSK2336805,from GlaxoSmithKline. Janssen is also developing the promising HCV protease inhibitor simeprevir (formerly TMC435), which is currently awaiting approval in the U.S. and Europe.

alt

EACS 2013: Simeprevir with Interferon Effective for Genotype 1 HIV/HCV Coinfected People

Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV positive people coinfected with HCV genotype 1, researchers reported at the 14th European AIDS Conference this week in Brussels. Particularly impressive was a 57% sustained response rate for prior null responders. Another study showed simeprevir to be active against HCV genotype 4 in monoinfected patients.

alt

IDWeek 2013: Daclatasvir Is Effective Against HCV with Interferon or in All-oral Regimen

A short 12- or 16-week triple regimen of daclatasvir plus pegylated interferon/ribavirin cured more people than a 24-week course of pegylated interferon/ribavirin alone, while an interferon-free regimen containing daclatasvir, asunaprevir, and BMS-791325 produced sustained response rates of around 90%, researchers reported at the Second IDWeek conference last week in San Francisco.

alt